Bristol-myers Squibb Compnay

Five Prime Therapeutics, Inc.

Xiaodi Deng

Alan J Korman

Guodong Chen

Richard Y Huang

Ekaterina G Deyanova

Andrew Rankin

Paul O Sheppard

Mark J Selby

Nils Lonberg

Arvind Rajpal

Ginger Chao Rakestraw

Linda Liang

Michelle Minhua Han

Keith Sadoon Bahjat

Christine Bee

Xiao Min Schebye

Robert J Johnston

Lin Hui Su

Luis Borges

Hong-An Truong

Joseph Toth

Jason Robert Pinckney

Diana Yuhui Chen

David A Critton

Pavel Strop

Akbar Nayeem

Chetana Rao-Naik

Michael Quigley

Hadia Lemar

Sayumi Yamazoe

Patrick G Holder

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies binding to ILT4

An antibody has a glutamine-containing extension at the C-terminus of a light chain thereof, making it suitable for conjugation via transglutaminase-mediated transamidation.

Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to vista at acidic pH

Growing community of inventors

San Mateo, CA, United States of America

Xiaodi Deng